<p>Surrozen, Inc.（納斯達克代碼：SRZN - 獲取免費報告）董事 Tim Kutzkey 於 11 月 13 日星期四收購了 315,457 股該公司的股票。該股票的平均收購價格為每股 12.65 美元，總價值為 3,990,531.05 美元。交易完成後，該董事在公司持有 962,718 股，估值約為 12,178,382.70 美元。此次交易使其持股增加了 48.74%。該交易已在與證券交易委員會的法律文件中披露，您可以通過此鏈接訪問。</p>
<h2>Surrozen 股票表現</h2>
<p>在週二的交易中，納斯達克 SRZN 的股價下跌 0.58 美元，達到 15.54 美元。該公司的交易量為 100,264 股，而其平均交易量為 92,641 股。Surrozen, Inc.的 52 周最低價為 5.90 美元，52 周最高價為 18.17 美元。該公司的 50 日移動平均價格為 13.51 美元，200 日移動平均價格為 11.11 美元。該股票的市值為 1.3318 億美元，市盈率為-0.70，貝塔值為 0.62。</p>
<p>Surrozen（納斯達克：SRZN - 獲取免費報告）最近於 11 月 7 日星期五發布了其財報。該公司報告本季度每股收益（EPS）為-3.61 美元，低於市場共識預期的-1.17 美元，差距為-2.44 美元。Surrozen 的淨利潤率為-2,909.10%，股本回報率為-4,055.04%。該公司本季度的收入為 98 萬美元。股票分析師預計 Surrozen, Inc.在本年度的每股收益將為-8.49 美元。</p>
<h2>對 Surrozen 的對沖基金看法</h2>
<p>一些對沖基金最近增加或減少了在 SRZN 的持股。Adage Capital Partners GP L.L.C.在第一季度將其在 Surrozen 的持股增加了 37.1%。Adage Capital Partners GP L.L.C.現在擁有 88,653 股該公司的股票，價值 1,034,000 美元，此前在上個季度又收購了 24,000 股。Driehaus Capital Management LLC 在第一季度收購了 Surrozen 的新股份，價值約為 2,390,000 美元。Stonepine Capital Management LLC 在第一季度將其在 Surrozen 的持股增加了 108.3%。Stonepine Capital Management LLC 現在擁有 285,782 股該公司的股票，價值 3,332,000 美元，此前在上個季度又購買了 148,582 股。RA Capital Management L.P.在第一季度將其在 Surrozen 的持股增加了 140.3%。RA Capital Management L.P.現在擁有 679,130 股該公司的股票，價值 7,919,000 美元，此前在上個季度又購買了 396,550 股。最後，Vivo Capital LLC 在第一季度收購了 Surrozen 的新股份，價值約為 3,032,000 美元。機構投資者持有該公司 66.57% 的股票。</p>
<h2>分析師設定新目標價</h2>
<p>幾家券商最近對 SRZN 發表了評論。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Surrozen 股票的 “賣出（d-）” 評級。Lifesci Capital 在 11 月 13 日星期四的研究報告中將 Surrozen 的評級上調至 “強力買入”。最後，Wall Street Zen 在週五的報告中將 Surrozen 的評級上調至 “賣出”。一位股票研究分析師對該股票給予了強力買入評級，兩位給予了買入評級，一位對該公司的股票給予了賣出評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價為 38.50 美元。</p>
<p><strong>獲取我們關於 SRZN 的最新報告</strong></p>
<h2>關於 Surrozen</h2>
<p>（獲取免費報告）</p>
<p>Surrozen, Inc.是一家臨牀階段的生物技術公司，發現並開發藥物候選物，以選擇性調節 Wnt 通路以促進組織修復。該公司正在開發針對多種疾病領域的抗體基礎治療，包括腸道、肝臟、視網膜、角膜、肺、腎臟、耳蝸、皮膚、胰腺和中樞神經系統的疾病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票而非 Surrozen</li>
<li>哪些華爾街分析師最準確？</li>
<li>華爾街的沉睡巨人：亞馬遜即將覺醒？</li>
<li>為什麼股票行業對成功投資至關重要？</li>
<li>雲端的絕殺：ServiceNow 的購物狂歡</li>
<li>如何開始投資於便士股票</li>
<li>在 MSCI 退市風波中，MSTR 的逆向投資案例</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Surrozen 嗎？</h2>
<p>在考慮 Surrozen 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Surrozen 並不在名單上。</p>
<p>雖然 Surrozen 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

SRZN

<p>Surrozen, Inc. 的董事 Tim Kutzkey 以每股 12.65 美元的價格購買了 315,457 股公司股票，總計 3,990,531.05 美元。這次收購使他的持股增加了 48.74%，現在擁有 962,718 股，價值 12,178,382.70 美元。該交易已在 SEC 文件中披露。Surrozen 的股票表現顯示近期下滑，交易量為 100,264 股，市值為 1.3318 億美元。分析師對該股票的評級不一，普遍目標價為 38.50 美元</p>

<p>Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey acquired 315,457 shares of the business's stock in a transaction on Thursday, November 13th. The stock was acquired at an average price of $12.65 per share, with a total value of $3,990,531.05. Following the transaction, the director owned 962,718 shares in the company, valued at approximately $12,178,382.70. The trade was a 48.74% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link.</p>
<div class="lb-trans"><p>Surrozen, Inc.（納斯達克代碼：SRZN - 獲取免費報告）董事 Tim Kutzkey 於 11 月 13 日星期四收購了 315,457 股該公司的股票。該股票的平均收購價格為每股 12.65 美元，總價值為 3,990,531.05 美元。交易完成後，該董事在公司持有 962,718 股，估值約為 12,178,382.70 美元。此次交易使其持股增加了 48.74%。該交易已在與證券交易委員會的法律文件中披露，您可以通過此鏈接訪問。</p>
</div><h2>Surrozen Stock Performance</h2>
<div class="lb-trans"><h2>Surrozen 股票表現</h2>
</div><p>Shares of NASDAQ SRZN traded down $0.58 during trading on Tuesday, reaching $15.54. The company had a trading volume of 100,264 shares, compared to its average volume of 92,641. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $18.17. The business's 50 day moving average price is $13.51 and its 200-day moving average price is $11.11. The stock has a market cap of $133.18 million, a PE ratio of -0.70 and a beta of 0.62.</p>
<div class="lb-trans"><p>在週二的交易中，納斯達克 SRZN 的股價下跌 0.58 美元，達到 15.54 美元。該公司的交易量為 100,264 股，而其平均交易量為 92,641 股。Surrozen, Inc.的 52 周最低價為 5.90 美元，52 周最高價為 18.17 美元。該公司的 50 日移動平均價格為 13.51 美元，200 日移動平均價格為 11.11 美元。該股票的市值為 1.3318 億美元，市盈率為-0.70，貝塔值為 0.62。</p>
</div><p>Surrozen (NASDAQ:SRZN - Get Free Report) last issued its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The business had revenue of $0.98 million during the quarter. Equities analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.</p>
<div class="lb-trans"><p>Surrozen（納斯達克：SRZN - 獲取免費報告）最近於 11 月 7 日星期五發布了其財報。該公司報告本季度每股收益（EPS）為-3.61 美元，低於市場共識預期的-1.17 美元，差距為-2.44 美元。Surrozen 的淨利潤率為-2,909.10%，股本回報率為-4,055.04%。該公司本季度的收入為 98 萬美元。股票分析師預計 Surrozen, Inc.在本年度的每股收益將為-8.49 美元。</p>
</div><h2>Hedge Funds Weigh In On Surrozen</h2>
<div class="lb-trans"><h2>對 Surrozen 的對沖基金看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in SRZN. Adage Capital Partners GP L.L.C. grew its position in Surrozen by 37.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company's stock worth $1,034,000 after acquiring an additional 24,000 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of Surrozen during the first quarter valued at about $2,390,000. Stonepine Capital Management LLC boosted its stake in shares of Surrozen by 108.3% during the first quarter. Stonepine Capital Management LLC now owns 285,782 shares of the company's stock valued at $3,332,000 after purchasing an additional 148,582 shares in the last quarter. RA Capital Management L.P. grew its holdings in shares of Surrozen by 140.3% during the first quarter. RA Capital Management L.P. now owns 679,130 shares of the company's stock worth $7,919,000 after purchasing an additional 396,550 shares during the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of Surrozen in the first quarter valued at approximately $3,032,000. Institutional investors own 66.57% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近增加或減少了在 SRZN 的持股。Adage Capital Partners GP L.L.C.在第一季度將其在 Surrozen 的持股增加了 37.1%。Adage Capital Partners GP L.L.C.現在擁有 88,653 股該公司的股票，價值 1,034,000 美元，此前在上個季度又收購了 24,000 股。Driehaus Capital Management LLC 在第一季度收購了 Surrozen 的新股份，價值約為 2,390,000 美元。Stonepine Capital Management LLC 在第一季度將其在 Surrozen 的持股增加了 108.3%。Stonepine Capital Management LLC 現在擁有 285,782 股該公司的股票，價值 3,332,000 美元，此前在上個季度又購買了 148,582 股。RA Capital Management L.P.在第一季度將其在 Surrozen 的持股增加了 140.3%。RA Capital Management L.P.現在擁有 679,130 股該公司的股票，價值 7,919,000 美元，此前在上個季度又購買了 396,550 股。最後，Vivo Capital LLC 在第一季度收購了 Surrozen 的新股份，價值約為 3,032,000 美元。機構投資者持有該公司 66.57% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several brokerages recently commented on SRZN. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Surrozen in a report on Wednesday, October 8th. Lifesci Capital upgraded Surrozen to a &#34;strong-buy&#34; rating in a research note on Thursday, November 13th. Finally, Wall Street Zen raised Surrozen to a &#34;sell&#34; rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $38.50.</p>
<div class="lb-trans"><p>幾家券商最近對 SRZN 發表了評論。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Surrozen 股票的 “賣出（d-）” 評級。Lifesci Capital 在 11 月 13 日星期四的研究報告中將 Surrozen 的評級上調至 “強力買入”。最後，Wall Street Zen 在週五的報告中將 Surrozen 的評級上調至 “賣出”。一位股票研究分析師對該股票給予了強力買入評級，兩位給予了買入評級，一位對該公司的股票給予了賣出評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價為 38.50 美元。</p>
</div><p><strong>Get Our Latest Report on SRZN</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 SRZN 的最新報告</strong></p>
</div><h2>About Surrozen</h2>
<div class="lb-trans"><h2>關於 Surrozen</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.</p>
<div class="lb-trans"><p>Surrozen, Inc.是一家臨牀階段的生物技術公司，發現並開發藥物候選物，以選擇性調節 Wnt 通路以促進組織修復。該公司正在開發針對多種疾病領域的抗體基礎治療，包括腸道、肝臟、視網膜、角膜、肺、腎臟、耳蝸、皮膚、胰腺和中樞神經系統的疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Surrozen</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Checkmate in the Cloud: ServiceNow's Shopping Spree</li>
<li>How to start investing in penny stocks</li>
<li>The Contrarian Case for MSTR Amid MSCI Delisting Debacle</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非 Surrozen</li>
<li>哪些華爾街分析師最準確？</li>
<li>華爾街的沉睡巨人：亞馬遜即將覺醒？</li>
<li>為什麼股票行業對成功投資至關重要？</li>
<li>雲端的絕殺：ServiceNow 的購物狂歡</li>
<li>如何開始投資於便士股票</li>
<li>在 MSCI 退市風波中，MSTR 的逆向投資案例</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Surrozen Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Surrozen 嗎？</h2>
</div><p>Before you consider Surrozen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Surrozen 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surrozen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Surrozen 並不在名單上。</p>
</div><p>While Surrozen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Surrozen 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Tim Kutzkey 購買了 315,457 股 Surrozen（納斯達克代碼：SRZN）的股票